Corporate ActionApr 27, 2026, 07:12 AM
COAG Files S-1/A for IPO of 11.76M Shares at $16-$18; Net Proceeds $180.3M
AI Summary
Hemab Therapeutics Holdings, Inc. (COAG) filed an S-1/A for its initial public offering of 11,764,706 shares of common stock, with an estimated price range of $16.00 to $18.00 per share. The company expects to raise approximately $180.3 million in net proceeds, which will fund clinical development for its lead assets, sutacimig and HMB-002, and other R&D programs. COAG is a clinical-stage biotechnology company focused on blood coagulation disorders, with sutacimig in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, and HMB-002 in Phase 1/2 for Von Willebrand Disease. The company reported a net loss of $63.9 million in 2025 and $48.7 million in 2024.
Key Highlights
- Initial public offering of 11,764,706 common shares.
- Estimated IPO price range: $16.00 to $18.00 per share.
- Expected net proceeds from IPO: approximately $180.3 million.
- Sutacimig (HMB-001) Phase 1/2 showed 19-87% reduction in ATBR.
- HMB-002 Phase 1/2 increased VWF and Factor VIII levels >1.5-fold.
- Net loss for 2025 was $(63.9) million.
- Net loss for 2024 was $(48.7) million.
- Cash, cash equivalents, marketable securities $185.5 million (Dec 31, 2025).